OKUR (OnKure) Cumulative Company Assets

Official company branding of OnKure Therapeutics Inc (OKUR)

The future of OnKure Therapeutics Inc (OKUR) remains uncertain due to a lack of revenue and the potential for early-stage targeted therapy trials to fail. Meanwhile, the business focuses on developing innovative PI3Ka inhibitors for breast cancer therapy without the risk of hyperglycemia. This chart illustrates the current share price, reaching 132.69, reflecting rising medical trial costs amid a total absence of commercial profit during the clinical research stage.

OnKure Therapeutics Inc (OKUR) Aggregate Company Assets: for the period 10/08/2024 - 11/01/2026

Financial and market metric breakdowns for onkuretherapeutics.com (OKUR)

- stock price and consensus target price:
Price Performance Chart OnKure Therapeutics|OKUR - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation OKUR|OKUR - Enterprise Value
- company book value details:
Book Value per Share OnKure Therapeutics|OKUR - Company Book Value|Capitalization to Book Value Ratio onkuretherapeutics.com|OKUR - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio OnKure Therapeutics Inc|OKUR - Long-Term Debt to Capital|Current Liabilities to Capital OnKure Therapeutics|OKUR - Company Debts|Debt to Net Assets Ratio OKUR|OKUR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings OnKure Therapeutics|Quick Liquidity Indicator onkuretherapeutics.com
- earnings and market multiples details:
OKUR - Net Income
Basic company analysis:OnKure (OKUR)
Core merchandise of OnKure Therapeutics Inc

Total assets reflect the aggregate volume of resources under the company's control, where a reverse calculation via ROA allows for an objective assessment of capital efficiency. An analysis of the total assets forecast reveals the dynamics of the asset base, which for OnKure Therapeutics Inc (OKUR) signifies the ability to fund the sustainable development of oncology drugs and maintain strict bio-waste disposal standards while optimizing research expenditures.

Key competitors

beigene.com - Aggregate Asset Value|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|HURA: Cumulative Company Assets|TARA - Company Total Assets|Fate Therapeutics (FATE) - Aggregate Company Assets|Aadi Bioscience - Aggregate Asset Value|TCRX (TScan Therapeutics Inc) - Company Total Assets|Company Assets Champions Oncology Corp CSBR|Aggregate Company Assets XBiotech Inc. (XBIT)|CVM - Company Assets|Aggregate Company Assets OS Therapies OSTX|RADX: Total Business Assets|ARTV - Aggregate Company Assets|ANL - Company Total Assets|VERU (Veru Inc.) - Cumulative Company Assets|tempesttx.com (TPST) - Company Total Assets|Aggregate Company Assets Xilio Therapeutics Inc|RENB: Aggregate Asset Value|Company Total Assets MURA|KAPA - Company Assets|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|APLM: Cumulative Company Assets|Tharimmune Inc - Aggregate Business Assets|ADVB: Company Total Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Assets sunshinebiopharma.com SBFM|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Company Total Assets PPBT (Purple Biotech Corp)|Company Total Assets American Oncology Network Inc AONC|BGNE - Aggregate Company Assets|Total Asset Value of Company CKPT|ELEV: Company Total Assets|Company Assets iCAD (ICAD)|Cumulative Company Assets IKNA|Company Total Assets Notable Labs Corp|Cumulative Company Assets VIRX (Viracta Therapeutics)|Aggregate Business Assets MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Company Total Asset Base Ascentage Pharma Group International (AAPGV)